Chu Yu-Waye 4
4 · CytomX Therapeutics, Inc. · Filed Feb 4, 2026
Research Summary
AI-generated summary of this filing
CytomX (CTMX) CMO Chu Yu‑Waye Receives 375,000‑Share Award
What Happened
Chu Yu‑Waye, Chief Medical Officer of CytomX Therapeutics (CTMX), received equity awards reported on Feb 2, 2026: 75,000 restricted stock units (RSUs) and a 300,000‑share derivative award (reported as a derivative grant, i.e., an option or similar). Both awards were granted at $0.00 purchase price (typical for compensation grants), so no cash was paid by the insider at grant.
Key Details
- Transaction date: February 2, 2026; filing accession: Feb 4, 2026. Reported as grants (code A).
- Awards: 75,000 RSUs (reported at $0.00) and a 300,000 derivative award (reported at $0.00).
- Vesting for the RSUs (F1): 1/3rd vests annually on March 15, with the first vesting March 15, 2027, contingent on continued service.
- Footnote F2: filing notes that 206,000 RSUs are included in the reported amounts.
- Vesting for the derivative award (F3): vests 1/48th each month starting Feb 2, 2026, so fully vested after four years, subject to continued service.
- Shares owned after the transaction: not specified in the provided summary of the filing.
- Timeliness: Filing covers the Feb 2, 2026 grants and was filed Feb 4, 2026; no late‑filing flag indicated in the provided data.
Context
- These are compensation grants, not open‑market purchases or sales. Grants at $0.00 are standard for RSUs/options and represent potential future ownership if vesting conditions are met.
- The 300,000 derivative award is subject to multi‑year vesting and is not immediately exercisable into shares except as it vests; it is not reported as an immediate sale or cashless exercise.
- For retail investors: such awards signal executive compensation alignment with shareholders (vesting over time) but are routine — they do not alone indicate the insider is buying or selling stock on market conviction.
Insider Transaction Report
Form 4
Chu Yu-Waye
Chief Medical Officer
Transactions
- Award
Common Stock
[F1][F2]2026-02-02+75,000→ 210,725 total - Award
Stock Option (Right to Buy)
[F3]2026-02-02+300,000→ 300,000 totalExercise: $6.09Exp: 2036-02-01→ Common Stock (300,000 underlying)
Footnotes (3)
- [F1]Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on March 15 of each year, with the first 1/3rd vesting on March 15, 2027, subject to the Reporting Person continuing as a service provider through each such date.
- [F2]Includes 206,000 RSUs.
- [F3]1/48th of the shares subject to the option vest on each monthly anniversary measured from February 2, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date.
Signature
/s/ Christopher Ogden, as Attorney-in-Fact for Yu-Waye Chu|2026-02-04